Minerva Neurosciences, Inc.
NASDAQ: NERV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Remy Luthringer
- Employees
- 8
- Headquarters
- Burlington, United States
- IPO year
- 2014
- Market cap
- $30.3M
- Website
- https://www.minervaneurosciences.com
Loading NERV…
Loading profile data…Frequently asked questions about NERV
What does Minerva Neurosciences, Inc. (NERV) do?
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managi...
Where does NERV trade?
Minerva Neurosciences, Inc. (NERV) trades on the NASDAQ Global Market.
What sector is NERV in?
Minerva Neurosciences, Inc. (NERV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Minerva Neurosciences, Inc.?
Remy Luthringer is the chief executive officer of Minerva Neurosciences, Inc. (NERV).
Where is Minerva Neurosciences, Inc. headquartered?
Minerva Neurosciences, Inc. is headquartered in United States.
Does NERV pay a dividend?
Minerva Neurosciences, Inc. (NERV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NERV go public?
Minerva Neurosciences, Inc. (NERV) completed its initial public offering in 2014.